Loading company…
Sonoma Biotherapeutics, based in California and founded in 2020, develops Treg cell therapies for autoimmune and inflammatory diseases.
Based in South San Francisco, US, Sonoma Biotherapeutics, Inc. was co-founded in 2020 by Alexander Rudensky, Fred Ramsdell, Jeffrey Bluestone (CEO) and Qizhi Tang. Its programs include SBT-77-7101, a CAR-based Treg cell therapy for refractory rheumatoid arthritis, and SBT-11-5301, a Teff conditioning biologic. As of August 2021 the company had raised USD 335 million from investors including Mirae Asset Venture Investment, Ally Bridge Group, Casdin Capital and Deep Track Capital.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in